New hope for tough cancers: testing powerful drug combos
NCT ID NCT02961101
Summary
This study is testing whether an immunotherapy drug (anti-PD-1) works better alone or when combined with other treatments for people whose cancers have returned or stopped responding to standard therapies. It will involve about 250 patients with various advanced cancers, including lymphomas and solid tumors. The main goals are to see if these combinations are safe and if they can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANCIES MULTIPLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.